Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13267449 | 1.00 | ALDH1A1 (0.54) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL8207250 | 0.84 | ALDH1A1 (0.56) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL9070740 | 0.83 | ALDH1A1 (0.40) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL13076693 | 0.83 | ALDH1A1 (0.40) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL178483 | 0.83 | ALDH1A1 (0.40) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL8284254 | 0.83 | CYP3A4 (0.42) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL178506 | 0.82 | SLC6A4 (0.47) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL7415500 | 0.82 | ALDH1A1 (0.39) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL15419067 | 0.82 | SLC6A4 (0.47) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 | |
| SCHEMBL10087245 | 0.82 | GPR139 (0.40) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2431362-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-8124634-B2 | CB1 receptor modulators | 7TM PHARMA A/S (DK) | 2012-02-28 | — | — | US | disclosed |
| WO-2010131669-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2010-11-18 | — | — | WO | disclosed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | disclosed |
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| US-7375136-B2 | pH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | EMORY UNIVERSITY | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | ALDH1A1 96/4885LMNA 3481/4885HTT 3325/4885 |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | CNR1, CNR2, GPR6 | ALDH1A1 3325/4885LMNA 4443/4885HTT 3207/4885 |
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | ALDH1A1 1778/4885LMNA 3402/4885HTT 4829/4885 |
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | GRIN1, GRIA4, GRIA1 | ALDH1A1 2194/4885LMNA 538/4885HTT 178/4885 |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | GRIN1, GRIN2B, GRIN3A | ALDH1A1 2602/4885LMNA 1371/4885HTT 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.